Companies / Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

Nasdaq: AMLXCIK 1658551CAMBRIDGE, MA

Financials · FY2025

Revenue$0
Net income$-144.74M
Total debt—
Cash$49.33M
Diluted EPS$-1.53
Shares outstanding111.4M

Ownership

111.4M shares outstanding · as of Jul 27, 2026
7.6%Insiders
Ownership
Insiders7.63%8,506,823
10%+ / strategic21.77%24,252,067
Institutions79.51%88,594,239
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 6

View all →
Insider% of sharesShares
Cohen Joshua BCEOCo-Chief Executive Officer · Director
3.22%3,583,548
Klee Justin B.CEOCo-Chief Executive Officer · Director
3.22%3,583,481
Milne George M JrDirector
0.73%812,881
Bedrosian Camille LChief Medical Officer
0.24%265,285
Frates James MChief Financial Officer
0.23%261,628
Mazzariello GinaFormerChief Legal Officer
0.19%209,090

Institutional holders 185

View all →
HolderValue% of shares
Fmr LLC$199.54M14.82%
BlackRock, Inc.$158.53M7.92%
Perceptive Advisors LLC$115.16M7.44%
TCG Crossover Management, LLC$75.43M5.60%
Vanguard Group Inc$70.12M5.21%
Janus Henderson Group PLC$69.26M4.47%
Commodore Capital LP$68.25M5.07%
Saturn V Capital Management LP$54.32M4.04%
Adage Capital Partners Gp, L.L.C.$49.49M3.20%
State Street Corporation$46.76M2.34%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 15, 2026Cohen Joshua B
CEO
SellCommon Stock$1.85M-136K
-3.87%
3,378,621
3.03% of shares
medium
Jan 15, 2026Klee Justin B.
CEO
SellCommon Stock$1.85M-136K
-3.87%
3,378,546
3.03% of shares
medium
Jan 15, 2026Cohen Joshua B
CEO
ExerciseCommon Stock$1.49M+197K
+5.94%
3,514,814
3.15% of shares
low
Jan 15, 2026Klee Justin B.
CEO
ExerciseCommon Stock$1.49M+197K
+5.94%
3,514,739
3.15% of shares
low
Mar 2, 2026Cohen Joshua B
CEO
SellCommon Stock$424.1K-29K
-0.87%
3,334,683
2.99% of shares
medium
Mar 2, 2026Klee Justin B.
CEO
SellCommon Stock$423.8K-29K
-0.87%
3,334,616
2.99% of shares
medium
Feb 2, 2026Klee Justin B.
CEO
SellCommon Stock$227.6K-16K
-0.46%
3,363,898
3.02% of shares
medium
Feb 2, 2026Cohen Joshua B
CEO
SellCommon Stock$227.6K-16K
-0.46%
3,363,965
3.02% of shares
medium

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—0—
Vanguard Group IncPassive13G—5,804,912—
Adage Capital Management, L.P.Passive13G/A———
BlackRock, Inc.Passive13G/A—7,783,648—
Fmr LLCPassive13G/A—16,468,419—
TCG Crossover GP II, LLCPassive13G/A———
Perceptive Advisors LLCPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
AMLX——03237H101—